8-K: CARGO Therapeutics to be Acquired by Concentra Biosciences in Cash and Contingent Value Rights Deal

CARGO Therapeutics, Inc. has entered into a definitive merger agreement to be acquired by Concentra Biosciences, LLC for $4.379 per share in cash plus a contingent value right.

Summary

• CARGO Therapeutics, Inc. (NASDAQ: CRGX) has signed a definitive merger agreement to be acquired by Concentra Biosciences, LLC.
• The acquisition price is $4.379 per share in cash, plus one non-transferable Contingent Value Right (CVR).
• The CVR entitles holders to receive: (i) 100% of CARGO's closing net cash exceeding $217.5 million, and (ii) 80% of net proceeds from any disposition of certain CARGO product candidates (CRG-022, CRG-023, and its allogeneic platform) within two years following the merger closing.
• CARGO's Board of Directors unanimously approved the merger, deeming it fair and in the best interests of all stockholders, and recommended that stockholders accept the Offer and tender their shares.
• Concentra is required to commence a cash tender offer by July 21, 2025, to acquire all outstanding shares.
• The closing of the tender offer is subject to certain conditions, including the tender of at least 50% plus one share of outstanding common stock and CARGO having at least $217.5 million in net cash at closing.
• CARGO's officers, directors, and certain stockholders, collectively holding approximately 17.4% of outstanding shares, have signed tender and support agreements.
• The merger transaction is expected to close in August 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the unanimous board approval, a definitive acquisition agreement providing immediate cash value, and potential upside through a CVR. However, the speculative nature and non-transferability of the CVR, along with the company's 'Wind-Down Process,' temper the overall sentiment from being extremely positive.

Positives

• The acquisition provides immediate liquidity and certainty for shareholders with a cash component of $4.379 per share.
• The Contingent Value Right (CVR) offers potential upside from CARGO's existing net cash above $217.5 million and future monetization of its product candidates (CRG-022, CRG-023, and allogeneic platform).
• CARGO's Board of Directors unanimously approved the merger, determining it to be fair and in the best interests of all stockholders.
• Significant insider support for the transaction, with officers, directors, and certain stockholders holding approximately 17.4% of outstanding shares agreeing to tender their shares.
• The transaction is not subject to a financing condition, which reduces execution risk.

Negatives

• The CVR is non-transferable, limiting liquidity for the contingent portion of the consideration.
• The CVR is highly speculative, with no assurance that holders will receive any payments from product dispositions.
• The CVR's disposition period is limited to two years, after which no payments will be made from dispositions.
• A termination fee of $3.8 million is payable by CARGO under certain circumstances, including if it enters into a superior proposal.
• CARGO is required to reimburse Concentra up to $0.5 million in expenses if Concentra terminates due to Closing Net Cash being less than $217.5 million.
• The company has been undergoing a 'Wind-Down Process,' which may suggest underlying operational challenges or a strategic shift prior to the acquisition.

Risks

• The possibility that various closing conditions for the merger may not be satisfied or waived, including uncertainties regarding the percentage of stockholders tendering their shares.
• The possibility that competing offers for CARGO Therapeutics will be made.
• The risk that the transactions may not be completed in a timely manner, or at all, which could adversely affect CARGO's business and stock price.
• Significant costs associated with the proposed transactions.
• The risk that any stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
• The risk that activities related to the CVR Agreement may not result in any value to the company's stockholders, as the CVR is highly speculative.
• The Closing Net Cash condition of no less than $217.5 million, which if not met, could lead to termination or expense reimbursement.

Future Outlook

The company expects the merger transaction to close in August 2025. Following the merger, CARGO will become a wholly-owned subsidiary of Concentra. The CVR mechanism provides a forward-looking opportunity for shareholders to potentially benefit from the company's existing net cash and future monetization of its product candidates (CRG-022, CRG-023, and allogeneic platform) within a two-year disposition period. However, the CVR is highly speculative, and there is no assurance of future payments from dispositions.

Management Comments

• The CARGO board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all CARGO stockholders and has approved the Merger Agreement and related transactions.
• The CARGO board of directors has unanimously... recommended that the Companys stockholders accept the Offer and tender their shares of Common Stock pursuant to the Offer.

Industry Context

This acquisition represents a strategic move by Concentra Biosciences to acquire CARGO Therapeutics, a biotechnology company focused on CAR T-cell therapies. The inclusion of a Contingent Value Right (CVR) tied to specific product candidates (CRG-022, CRG-023, and an allogeneic platform) suggests that Concentra sees potential value in these assets beyond the immediate cash consideration, but also indicates a degree of uncertainty or a desire to share future upside with existing shareholders rather than paying a higher upfront premium. This structure is common in biotech acquisitions where the value of pipeline assets is uncertain or requires further development/monetization efforts. The 'Wind-Down Process' mentioned for CARGO's business suggests that the company may have been facing challenges or a strategic pivot, making an acquisition a viable exit strategy.

Comparison to Industry Standards

• The use of a CVR in biotech acquisitions is a common mechanism to bridge valuation gaps between buyers and sellers, particularly for early-stage or unproven assets. Similar structures have been observed in acquisitions such as Sanofi's acquisition of Kadmon Holdings (CVR for Rezurock sales) or Roche's acquisition of Spark Therapeutics (CVR for Hemophilia A gene therapy approval).
• The specific CVR terms (100% of net cash above a threshold, 80% of net disposition proceeds for specific assets within a two-year window) are tailored to CARGO's financial position and pipeline, aligning with common practices for contingent payments in the industry.
• The $217.5 million net cash threshold for the CVR suggests a baseline valuation or operational need for Concentra, a common element in such deals.
• The 17.4% stockholder support from insiders (officers, directors, and certain stockholders) is a strong indicator of confidence in the deal from key stakeholders, aligning with typical insider support levels seen in similar transactions.
• The termination fee of $3.8 million and expense reimbursement of up to $0.5 million are within the customary range for transactions of this size in the biotech sector, typically representing a small single-digit percentage of the equity value.

Management Changes

Corporate Governance

Legal Proceedings

• No material Proceeding pending or threatened against CARGO as of the Agreement Date.
• The risk of stockholder litigation in connection with the Transactions is noted in forward-looking statements.

Related Party Transactions

• Tang Capital Partners, LP, a Delaware limited partnership, delivered a limited guaranty in favor of CARGO, concurrently with the execution of the Merger Agreement and CVR Agreement. Tang Capital Management, LLC is the sole manager of Parent (Concentra Biosciences, LLC) and the general partner of Guarantor (Tang Capital Partners, LP), indicating a related party transaction.

Stakeholder Impact

• Shareholders: Will receive $4.379 in cash per share and one non-transferable CVR, offering immediate cash and potential future upside from asset dispositions and net cash.
• Employees: Company Stock Options and Restricted Stock Units will be converted into cash and CVRs. Retention bonus letters and separation agreements are in place for certain employees, indicating a structured wind-down or transition.
• Customers/Suppliers: The document does not directly address impact on customers or suppliers, but the 'Wind-Down Process' suggests a cessation or transfer of existing operations.
• Creditors: Indebtedness of the Company is a factor in the Closing Net Cash calculation, which is a condition for the offer, implying creditors will be addressed as part of the transaction.

Next Steps

• Concentra Biosciences to commence the cash tender offer by July 21, 2025.
• CARGO Therapeutics to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• Merger Sub to merge with CARGO Therapeutics following the completion of the tender offer.
• CARGO's securities to be de-listed from Nasdaq and de-registered under the Exchange Act as promptly as practicable following the Effective Time, and in any event no more than ten (10) days after the Merger Closing Date.
• Parent and Merger Sub to enter into a Contingent Value Rights Agreement with a rights agent at or prior to the Offer Closing Time.
• Parent and Merger Sub to use commercially reasonable efforts to seek, negotiate, and execute Disposition Agreements for CVR Products during the Disposition Period (two years post-merger).

Key Dates

Recommendation

Keywords

CARGO Therapeutics, Concentra Biosciences, Merger Agreement, Tender Offer, Acquisition, Contingent Value Right, CVR, Biotechnology, CAR T-cell therapy, CRG-022, CRG-023, Allogeneic platform, SEC filing, 8-K, Corporate Action, Stockholders, NASDAQ, CRGX